基线DCE-MRI组学对乳腺癌患者新辅助化疗疗效预测的应用研究

Application of Baseline DCE-MRI Radomics for Prediction of Efficacy of Neoadjuvant Chemotherapy in Breast Cancer Patients

新辅助化疗是大多数浸润性乳腺癌患者的标准治疗方案,可以使肿瘤降期、提高保乳率、观察患者药敏性等,为后续治疗提供依据。目前新辅助化疗仍处于不断发展的阶段,病理完全缓解是患者最理想结局,与预后密切相关。本文以基线DCE-MRI组学对乳腺癌患者新辅助化疗的疗效预测进行综述。

Neoadjuvant chemotherapy is the standard treatment plan for most patients with invasive breast cancer,which can descent tumor stage,improve breast conservation rates,observe drug sensitivity and provide a basis for subsequent treatment.At present,neoadjuvant chemotherapy is still in the continuous stage of development,and pathological complete response is the most ideal outcome for patients,and it is closely related to the prognosis.This review summarizes the efficacy prediction of neoadjuvant chemotherapy in breast cancer patients using baseline enhanced MR radiomics.